Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction.

[1]  O. Hess,et al.  Vasoconstriction of stenotic coronary arteries during dynamic exercise in patients with classic angina pectoris: reversibility by nitroglycerin. , 1986, Circulation.

[2]  O. Hess,et al.  Coronary stenosis vasomotion during dynamic exercise before and after PTCA. , 1989, European heart journal.

[3]  O. Hess,et al.  Coronary vasomotor tone during static and dynamic exercise. , 1989, European heart journal.

[4]  E. Nabel,et al.  Atherosclerosis influences the vasomotor response of epicardial coronary arteries to exercise. , 1989, The Journal of clinical investigation.

[5]  J. Badimón,et al.  Rapamycin inhibits vascular smooth muscle cell migration. , 1996, The Journal of clinical investigation.

[6]  J. Roelandt,et al.  Images in Cardiovascular Medicine , 2000 .

[7]  R. Virmani,et al.  Pathological Analysis of Local Delivery of Paclitaxel Via a Polymer-Coated Stent , 2001, Circulation.

[8]  P. Tsao,et al.  Stent-Based Delivery of Sirolimus Reduces Neointimal Formation in a Porcine Coronary Model , 2001, Circulation.

[9]  Ranz,et al.  DECREASED RATE OF CORONARY RESTENOSIS AFTER LOWERING OF PLASMA HOMOCYSTEINE LEVELS , 2001 .

[10]  Lack of Neointimal Proliferation After Implantation of Sirolimus-Coated Stents in Human Coronary Arteries: A Quantitative Coronary Angiography and Three-Dimensional Intravascular Ultrasound Study , 2001 .

[11]  P. Serruys,et al.  Angiographic Findings of the Multicenter Randomized Study With the Sirolimus-Eluting Bx Velocity Balloon-Expandable Stent (RAVEL): Sirolimus-Eluting Stents Inhibit Restenosis Irrespective of the Vessel Size , 2002, Circulation.

[12]  P. Serruys,et al.  Intravascular Ultrasound Findings in the Multicenter, Randomized, Double-Blind RAVEL (RAndomized study with the sirolimus-eluting VElocity balloon-expandable stent in the treatment of patients with de novo native coronary artery Lesions) Trial , 2002, Circulation.

[13]  G. Koehl,et al.  Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor , 2002, Nature Medicine.

[14]  F. Eberli,et al.  Exercise-Induced Coronary Artery Vasodilation Is Not Impaired by Stent Placement , 2002, Circulation.

[15]  P. Serruys,et al.  A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. , 2002, The New England journal of medicine.

[16]  Antonio Colombo,et al.  Mechanism of Late In-Stent Restenosis After Implantation of a Paclitaxel Derivate–Eluting Polymer Stent System in Humans , 2002, Circulation.

[17]  P. Serruys,et al.  Two-Year Angiographic and Intravascular Ultrasound Follow-Up After Implantation of Sirolimus-Eluting Stents in Human Coronary Arteries , 2003, Circulation.

[18]  Jeffrey W Moses,et al.  Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. , 2003, The New England journal of medicine.

[19]  Patrick W Serruys,et al.  Unrestricted Utilization of Sirolimus-Eluting Stents Compared With Conventional Bare Stent Implantation in the “Real World”: The R apamycin-E luting S tent E valuated A t R otterdam C ardiology H ospital (RESEARCH) Registry , 2004, Circulation.

[20]  J. Moses,et al.  Sirolimus-eluting stents vs. standard stents in patients with stenosis in a native coronary artery , 2004 .

[21]  R. Virmani,et al.  Images in cardiovascular medicine. Vascular healing 4 years after the implantation of sirolimus-eluting stent in humans: a histopathological examination. , 2004, Circulation.

[22]  David J Cohen,et al.  Stent Thrombosis After Successful Sirolimus-Eluting Stent Implantation , 2004, Circulation.

[23]  Patrick W Serruys,et al.  Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy , 2004, The Lancet.

[24]  Giuseppe Musumeci,et al.  Localized Hypersensitivity and Late Coronary Thrombosis Secondary to a Sirolimus-Eluting Stent: Should We Be Cautious? , 2004, Circulation.

[25]  R. Virmani,et al.  Preclinical restenosis models and drug-eluting stents: still important, still much to learn. , 2004, Journal of the American College of Cardiology.

[26]  O. Hess,et al.  Deleterious Effect of Coronary Brachytherapy on Vasomotor Response to Exercise , 2004, Circulation.

[27]  Charles L. Brown,et al.  Analysis of 1-Year Clinical Outcomes in the SIRIUS Trial: A Randomized Trial of a Sirolimus-Eluting Stent Versus a Standard Stent in Patients at High Risk for Coronary Restenosis , 2004, Circulation.

[28]  Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy , 2005 .